St. Jude Medical has received CE Mark approval from European regulators for its Trifecta replacement cardiac valve. The pericardium tissue-based device is designed to closely mimic the heart's natural blood flow.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan